Champions Oncology Inc (NASDAQ:CSBR) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 183,000 shares, a decline of 12.0% from the July 31st total of 207,900 shares. Based on an average daily volume of 27,600 shares, the days-to-cover ratio is presently 6.6 days. Currently, 4.3% of the company’s stock are short sold.
A number of hedge funds have recently added to or reduced their stakes in the stock. River & Mercantile Asset Management LLP bought a new position in Champions Oncology in the 2nd quarter valued at approximately $1,082,000. Susquehanna International Group LLP lifted its position in Champions Oncology by 51.0% in the 2nd quarter. Susquehanna International Group LLP now owns 24,510 shares of the biotechnology company’s stock valued at $192,000 after acquiring an additional 8,279 shares in the last quarter. BlackRock Inc. lifted its position in Champions Oncology by 12.0% in the 2nd quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock valued at $1,073,000 after acquiring an additional 14,733 shares in the last quarter. Alambic Investment Management L.P. lifted its position in Champions Oncology by 27.0% in the 2nd quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock valued at $538,000 after acquiring an additional 14,614 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Champions Oncology by 110.4% during the 2nd quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock valued at $1,167,000 after buying an additional 78,250 shares during the last quarter. 52.55% of the stock is currently owned by institutional investors and hedge funds.
CSBR stock traded down $0.19 during midday trading on Thursday, hitting $6.26. The company’s stock had a trading volume of 18,048 shares, compared to its average volume of 42,916. The company has a market cap of $76.69 million, a PE ratio of 626.00 and a beta of 1.16. Champions Oncology has a 12 month low of $5.20 and a 12 month high of $17.90. The firm’s 50-day moving average is $6.03 and its 200-day moving average is $8.22.
Champions Oncology (NASDAQ:CSBR) last released its quarterly earnings data on Monday, July 15th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.05). The business had revenue of $7.72 million during the quarter, compared to the consensus estimate of $6.60 million. Champions Oncology had a net margin of 0.47% and a return on equity of 7.16%. On average, equities analysts predict that Champions Oncology will post 0.25 earnings per share for the current year.
CSBR has been the topic of several analyst reports. Zacks Investment Research cut Champions Oncology from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 25th. Janney Montgomery Scott cut Champions Oncology from a “buy” rating to a “neutral” rating in a research report on Wednesday, July 24th.
Champions Oncology Company Profile
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Recommended Story: What economic reports are most valuable to investors?
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.